Table 1. Univariate cox regression analysis for progression-free survival and overall survival for the clinicopathologic features of 104 patients.
| Clinical factors | Patients (n) | PFS | OS | |||
| HR (95% CI) | P value | HR (95% CI) | P value | |||
| Gender | 0.053 | |||||
| Male | 86 | 1.00 | 1.00 | |||
| Female | 18 | 0.64 (0.30–1.34) | 0.231 | 0.31 (0.10–1.02) | ||
| Age (years) | 0.436 | |||||
| <65 | 43 | 1.00 | 1.00 | |||
| ≥65 | 61 | 0.88 (0.53–1.47) | 0.625 | 0.79 (0.43–1.44) | ||
| Smoking (pack-year) | 0.084 | |||||
| <30 | 33 | 1.00 | 1.00 | |||
| ≥30 | 71 | 0.99 (0.58–1.70) | 0.980 | 1.864 (0.92–3.78) | ||
| ECOG | 0.197 | |||||
| 0 | 46 | 1.00 | 1.00 | |||
| 1 | 58 | 1.29 (0.779–2.139) | 0.323 | 1.49 (0.81–2.73) | ||
| Location type | 0.423 | |||||
| Central type | 31 | 1.00 | 1.00 | |||
| Peripheral type | 73 | 0.667 (0.395–1.126) | 0.129 | 0.77 (0.41–1.45) | ||
| Histology | ||||||
| Squamous cell carcinoma | 51 | 1.00 | 0.458 | 1.00 | 0.021 | |
| Adenocarcinoma | 43 | 1.388 (0.571–3.372) | 0.413 | 0.45 (0.23–0.87) | 0.018 | |
| No specific type | 10 | 1.051 (0.425–2.598) | 0.260 | 0.35 (0.12–1.02) | 0.055 | |
| Stage | 0.002 | |||||
| I–II | 42 | 1.00 | 1.00 | |||
| III–IV | 62 | 2.406 (1.380–4.195) | 0.002 | 3.102 (1.52–6.33) | ||
| BED | 0.032 | |||||
| <70 | 16 | 1.00 | 1.00 | |||
| ≥70 | 88 | 0.594 (0.308–1.144) | 0.119 | 0.45 (0.21–0.93) | ||
| Chemotherapy | 0.019 | |||||
| No | 51 | 1.00 | 1.00 | |||
| Yes | 53 | 1.62 (0.97–2.72) | 0.065 | 2.12 (1.13–3.96) | ||
PFS, progression-free survival; OS, overall survival; HR, hazard ratio; CI, confidence interval; ECOG, Eastern Cooperative Oncology Group; BED, Biological effective dose.